Everolimus is a mammalian-target-of-rapamycin (m-Tor) inhibitor used originally primarily for treatment of transplant patients. The strong immunosuppressive properties of the drug led to an important position in the pharmacological treatment of renal, heart and liver transplant patients. Additionally Everolimus has obtained a place in the treatment of certain types of cancers as advanced renal cell carcinoma, advanced pancreatic neuroendocrine tumors, advanced hormone receptor-positive, HER2-negative breast cancer. Also for renal angiomyolipomas efficacy has been established. In drug-eluting coronary stents the immunosuppressant Everolimus prevents stenosis. For treatment of tumors associated with the orphan disease tuberous sclerosis complex (TSC) the drug is very efficacious. The pharmacokinetics of Everolimus are under influence of many factors making frequent therapeutic drug monitoring obligatory in transplant patients and TSC patients with subependymal giant cell astrocytoma. Therapeutic drug monitoring has therefore obtained an important place in the treatment of these patients on Everolimus.
Monitoring of Everolimus with the easy and friendly DBS method makes it possible to perform therapeutic drug monitoring at any time and at any place. The regular therapeutic drug monitoring often consist of a fasting blood test. DBS allows the patient to perform the blood sampling at ease at home before breakfast and send the blood sample to DBSL by post for analysis. DBSL will inform her/him on the receipt of the blood sample. The physician will receive the measured blood drug level in due course. DBSL makes use of state of the art LC-MS/MS technology to assess the Everolimus blood level.